1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Physician Views: Reaction to Bristol-Myers Squibb's Opdivo data in non-small-cell lung cancer

Physician Views: Reaction to Bristol-Myers Squibb's Opdivo data in non-small-cell lung cancer

  • November 2014
  • ID: 2506825
  • Format: PDF
  • By Firstword Pharma

Summary






Studies of Bristol-Myers Squibb's PD-1 inhibitor nivolumab in non-small-cell lung cancer (NSCLC) have been watched closely by investors, analysts and the oncology community, given both the high level of unmet need in this indication and the size of the commercial opportunity.

Nivolumab, which is branded as Opdivo, is forecast to generate global sales of around $6 billion by the end of the decade, with a significant proportion attributed to lung cancer.

Little surprise then, perhaps, that Bristol-Myers Squibb's share price jumped some 9 percent last week when positive data from the Phase II Checkmate-063 study, assessing Opdivo in third-line squamous NSCLC patients, were unveiled (ViewPoints: Investors respond in kind to impressive data for Bristol-Myers Squibb NSCLC immunotherapy).

Checkmate-063 recruited 117 patients, each of whom had failed two prior lines of therapy. They were dosed 3mg/kg of Opdivo every two weeks until progression with the study producing an overall response rate (ORR) of 15 percent and a one-year survival rate of 41 percent.

Contextualising the Checkmate-063 data nevertheless remains challenging, given both the single-arm design of the study and a lack of historical data. In a note to investors, ISI analyst Mark Schoenebaum suggested that the "numbers to beat" for Opdivo in this setting were an estimated ORR in the mid-single digits and a one-year survival rate of around 20 percent.

However, Sanford C. Bernstein analyst Tim Anderson was slightly more cautious towards the historical benchmarking for the all important one-year survival rate, noting that a 21 percent rate (or 18 percent for squamous patients) cited by Bristol-Myers Squibb stemmed from a database comprising only Medicare patients aged 66 years or older. This may be an older patient population than that enrolled in Checkmate-063, added Anderson.

Benchmarking Opdivo's impressive looking overall survival rate is particularly important given the nature of these immunotherapies, which are not effective in all patients, but in those who are responsive can result in long, durable responses. This characteristic raises the prospect, particularly in European markets perhaps, that some stratification of patients may be encouraged before usage is approved. Key opinion leaders recently interviewed by FirstWord's Therapy Trends team have alluded to this occurring.

One key question stemming from the Checkmate-063 data is whether it alone will be sufficient to support approval in the third-line squamous indication, or whether the FDA will also choose to assess interim data from the ongoing Checkmate-017 study, which is comparing Opdivo to Taxotere in second-line squamous NSCLC patients. Squamous patients are not only more difficult to treat, but there are also no approved therapies in the third-line setting. Furthermore, around 65 percent of the patients enrolled in Checkmate-063 had been heavily pre-treated, previously receiving four or more lines of therapy.

The other key question is whether data from Checkmate-063 has any read-across to Checkmate-017. In a Phase I study, Opdivo was shown to demonstrate a dose-dependent one-year survival rate among squamous and non-squamous patients of between 42 percent and 56 percent, while Taxotere has previously demonstrated one-year survival rates of between 34 percent and 36 percent in the second-line setting.








In response to the Checkpoint-063 data, we are polling US and EU5-based oncologists with the following questions...


Based on your assessment, how accurate is a cited historical one-year survival rate of 18 percent among third-line squamous NSCLC patients?

What percentage of squamous NSCLC patients would you estimate progress to the third-line setting?

Based on newly published Phase II data for nivolumab from the Checkpoint-063 study – see http://news.bms.com/press-release/rd-news/phase-2-objective-response-rat... – to what percentage of third-line squamous NSCLC patients would you expect to prescribe the drug 12 months after launch?

Would you expect payers to exert any pressure on you to stratify patients (by higher PD-L1 status) before utilising this therapy in the third-line setting, based on the Phase II data?

Based on the Phase II data from Checkpoint-063 (third-line squamous NSCLC), how confident are you that nivolumab will produce data sufficient to drive significant usage in second-line squamous NSCLC patients? Nivolumab is currently being assessed head-to-head versus Taxotere in a Phase III study in this indication (note: Taxotere has previously demonstrated one-year survival rates of between 34 percent and 36 percent in the second-line setting).


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2014

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on